ResearcherVirginia Commonwealth UniversityActive in the last 2 years
Parash Parajuli
Matched on ORCID iD 0000-0002-5023-3756; OpenAlex author ID A5059085312. Sources: OpenAlex.
Their work
- Papers
- 6 (first author 4, last author 0)
- Trials
- 0
- Grants
- 0
- Labs led
- 0
- Collaborators
- 8
2019: 1 paper · 2020: 1 paper · 2021: none · 2022: 1 paper · 2023: 2 papers · 2024: none · 2025: none · 2026: 1 paper
Papers 6
- NF1 loss of function as an alternative initiating event in pancreatic ductal adenocarcinoma. First author DOI 10.1016/j.celrep.2026.117066↗
- Deciphering epithelial-to-mesenchymal transition in pancreatic cancer. First author DOI 10.1016/bs.acr.2023.02.008↗
- Antagonism between Prdm16 and Smad4 specifies the trajectory and progression of pancreatic cancer. First author DOI 10.1083/jcb.202203036↗
- NF1 loss of function as an alternative initiating event in pancreatic ductal adenocarcinoma. First author DOI 10.1016/j.celrep.2022.111623↗
- Pancreatic cancer triggers diabetes through TGF-β-mediated selective depletion of islet β-cells. Co-author DOI 10.26508/lsa.201900573↗
- TGIF1 functions as a tumor suppressor in pancreatic ductal adenocarcinoma. Co-author DOI 10.15252/embj.2018101067↗
Closest collaborators
The 8 strongest of 8 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.
- Mohammed Shawkat Razzaque · 6 shared papers, 2019–2026 · strength 1.11
- Paper NF1 loss of function as an alternative initiating event in pancreatic ductal adenocarcinoma. DOI 10.1016/j.celrep.2026.117066↗
- Paper Deciphering epithelial-to-mesenchymal transition in pancreatic cancer. DOI 10.1016/bs.acr.2023.02.008↗
- Paper Antagonism between Prdm16 and Smad4 specifies the trajectory and progression of pancreatic cancer. DOI 10.1083/jcb.202203036↗
- Azeddine Atfi · 6 shared papers, 2019–2026 · strength 1.11
- Paper NF1 loss of function as an alternative initiating event in pancreatic ductal adenocarcinoma. DOI 10.1016/j.celrep.2026.117066↗
- Paper Deciphering epithelial-to-mesenchymal transition in pancreatic cancer. DOI 10.1016/bs.acr.2023.02.008↗
- Paper Antagonism between Prdm16 and Smad4 specifies the trajectory and progression of pancreatic cancer. DOI 10.1083/jcb.202203036↗
- Creighton Friend · 4 shared papers, 2022–2026 · strength 0.88
- Paper NF1 loss of function as an alternative initiating event in pancreatic ductal adenocarcinoma. DOI 10.1016/j.celrep.2026.117066↗
- Paper Deciphering epithelial-to-mesenchymal transition in pancreatic cancer. DOI 10.1016/bs.acr.2023.02.008↗
- Paper Antagonism between Prdm16 and Smad4 specifies the trajectory and progression of pancreatic cancer. DOI 10.1083/jcb.202203036↗
- Keli Xu · 5 shared papers, 2019–2026 · strength 0.84
- Paper NF1 loss of function as an alternative initiating event in pancreatic ductal adenocarcinoma. DOI 10.1016/j.celrep.2026.117066↗
- Paper Antagonism between Prdm16 and Smad4 specifies the trajectory and progression of pancreatic cancer. DOI 10.1083/jcb.202203036↗
- Paper NF1 loss of function as an alternative initiating event in pancreatic ductal adenocarcinoma. DOI 10.1016/j.celrep.2022.111623↗
- Eric G. Hurwitz · 3 shared papers, 2022–2026 · strength 0.62
- Paper NF1 loss of function as an alternative initiating event in pancreatic ductal adenocarcinoma. DOI 10.1016/j.celrep.2026.117066↗
- Paper Antagonism between Prdm16 and Smad4 specifies the trajectory and progression of pancreatic cancer. DOI 10.1083/jcb.202203036↗
- Paper NF1 loss of function as an alternative initiating event in pancreatic ductal adenocarcinoma. DOI 10.1016/j.celrep.2022.111623↗
- Gopalakrishnan Ramakrishnan · 2 shared papers, 2022–2026 · strength 0.46
- Allyn Bryan · 1 shared paper, 2023 · strength 0.16
- Zhe Wang · 1 shared paper, 2019 · strength 0.09
How to reach this person
A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.